FY2027 Earnings Forecast for Cartesian Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:RNAC)

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Stock analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for shares of Cartesian Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($7.10) for the year. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($1.50) per share.

Several other equities research analysts have also issued reports on RNAC. Needham & Company LLC began coverage on Cartesian Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $42.00 price target for the company. HC Wainwright lifted their price target on Cartesian Therapeutics from $2.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday. Finally, SVB Leerink assumed coverage on Cartesian Therapeutics in a report on Tuesday. They set an “outperform” rating and a $39.00 price target for the company.

Cartesian Therapeutics Price Performance

Shares of NASDAQ RNAC opened at $20.59 on Wednesday. Cartesian Therapeutics has a one year low of $11.66 and a one year high of $42.60. The business’s 50-day simple moving average is $19.32.

Cartesian Therapeutics (NASDAQ:RNAC) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($2.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($2.10). Cartesian Therapeutics had a negative return on equity of 58.21% and a negative net margin of 845.01%. The business had revenue of $8.27 million for the quarter.

Insider Buying and Selling

In other Cartesian Therapeutics news, Director Timothy A. Springer purchased 21,612 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were bought at an average cost of $16.20 per share, with a total value of $350,114.40. Following the transaction, the director now directly owns 1,017,228 shares in the company, valued at approximately $16,479,093.60. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders purchased 22,472 shares of company stock worth $365,981. 31.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cartesian Therapeutics stock. Hall Laurie J Trustee purchased a new position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 52,775 shares of the company’s stock, valued at approximately $34,000. Hall Laurie J Trustee owned 0.98% of Cartesian Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 86.95% of the company’s stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.